Targeting localized immune suppression within the tumor through repeat cycles of immune cell-oncolytic virus combination therapy.

ABSTRACT: A major limitation to the use of immunotherapy in the treatment of cancer has been the localized immune suppressive environment within the tumor. Although there is evidence that tumor-selective (oncolytic) viruses may help to overcome this immune suppression, a primary limitation to their use has been limited systemic delivery potential, especially in the face of antiviral immunity. We recently demonstrated that tumor-trafficking immune cells can efficiently deliver oncolytic viral therapies to their tumor targets. These cells act as both a therapeutic agent and also a carrier vehicle for the oncolytic virus. Here, we demonstrate that such delivery is also possible in the face of pre-existing antiviral immunity, so overcoming the limited systemic delivery of naked, cell-free virus. It was

SUBMITTER: Thorne SH 

PROVIDER: S-EPMC2956933 | biostudies-literature | 2010 Sep

REPOSITORIES: biostudies-literature